<SEC-DOCUMENT>0001193125-24-282415.txt : 20241220
<SEC-HEADER>0001193125-24-282415.hdr.sgml : 20241220
<ACCEPTANCE-DATETIME>20241220060758
ACCESSION NUMBER:		0001193125-24-282415
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20241220
FILED AS OF DATE:		20241220
DATE AS OF CHANGE:		20241220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		241564971

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d919252d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of
December 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In December 2024, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><U>Exhibit No.</U></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><U>Description</U></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><A HREF="d919252dex991.htm">Tolebrutinib designated Breakthrough Therapy by the FDA for <FONT STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive multiple sclerosis </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit 99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><A HREF="d919252dex992.htm">Duvakitug positive phase 2b results demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> potential in ulcerative colitis and Crohn&#146;s disease
 </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: December&nbsp;20, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">/s/ Alexandra Roger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d919252dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g919252g01m04.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Tolebrutinib designated Breakthrough Therapy by the FDA <FONT
STYLE="white-space:nowrap">for&nbsp;non-relapsing</FONT> secondary progressive multiple sclerosis </I></FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Designation is based on positive results from the HERCULES study in adults with
<FONT STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive multiple sclerosis (nrSPMS) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Tolebrutinib is the first and only brain-penetrant BTK inhibitor in MS to be designated Breakthrough Therapy by the FDA
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><B>Paris, December</B><B></B><B>&nbsp;13, 2024.</B> The US Food and Drug Administration (FDA) has granted Breakthrough Therapy
designation to tolebrutinib for the treatment of adults with <FONT STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive multiple sclerosis (nrSPMS). This is based on positive results from the <U><FONT
STYLE="font-family:arial" COLOR="#7a00e6">HERCULES</FONT></U><FONT STYLE="font-family:arial"> phase 3 study, demonstrating that tolebrutinib delayed the time to onset of <FONT STYLE="white-space:nowrap">6-month</FONT> confirmed disability
progression (CDP), by 31% compared to placebo (HR 0.69; 95% CI <FONT STYLE="white-space:nowrap">0.55-0.88;</FONT> p=0.0026), with further analysis of secondary endpoints demonstrating that the number of participants who experienced confirmed
disability improvement was nearly double with tolebrutinib (10%) compared to those on placebo (5%) (HR 1.88; 95% CI 1.10 to 3.21; nominal p=0.021). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">FDA Breakthrough Therapy designation is designed to expedite the development and review of medicines in the US that target serious or life-threatening
conditions. Medicines qualifying for this designation must show preliminary clinical evidence that the drug may demonstrate substantial improvement on clinically significant endpoints over available medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Erik Wallstr&ouml;m, MD, PhD </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Global Head of Neurology Development, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;This Breakthrough Therapy designation demonstrates the potential for tolebrutinib to delay disability progression, a
critical unmet need for people living with multiple sclerosis. We look forward to working with the FDA during the regulatory review of this first of its kind medicine in <FONT STYLE="white-space:nowrap">non-relapsing</FONT> secondary progressive
multiple sclerosis where there are currently no approved treatments available.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Liver enzyme elevations (&gt;3xULN) were observed in 4.1%
of participants receiving tolebrutinib compared with 1.6% in the placebo group. A small (0.5%) proportion of participants in the tolebrutinib group experienced peak ALT increases of &gt;20xULN, all occurring within the first 90 days of treatment.
All but one case of liver enzyme elevations resolved without further medical intervention. The implementation of more frequent monitoring has helped mitigate serious liver sequelae.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Regulatory submissions of tolebrutinib are currently being finalized for the US and prepared for the EU. As with other medicines, Sanofi plans to
confirm once a regulatory submission for tolebrutinib has been accepted. The PERSEUS phase 3 study in primary progressive MS is currently ongoing with study results anticipated in H2 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Tolebrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About multiple sclerosis </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Multiple sclerosis is a chronic, immune-mediated, neurodegenerative disease that may result in accumulation of irreversible disabilities over time. The
physical and cognitive disability impairments translate into gradual deterioration of health status, impacting patients&#146; care and quality of life. Disability accumulation remains the significant unmet medical need in MS. To date, the primary
target of current medicines has been peripheral B and T cells, while innate immunity, which is believed to drive disability accumulation, remains largely unaddressed by current medicines. Currently approved, or late-stage medicines being tested
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g919252g04g04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">
for MS mainly target the adaptive immune system and/or do not act directly within the central nervous system to drive clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">nrSPMS refers to people with MS who have stopped experiencing relapses but continue to accumulate disability, experienced as symptoms such as fatigue,
cognitive impairment, balance and gait impairment, loss of bowel and/or bladder function, sexual disfunction, amongst others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About tolebrutinib </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Tolebrutinib is an investigational, oral, brain-penetrant, and bioactive Bruton&#146;s tyrosine kinase (BTK) inhibitor that achieves cerebrospinal fluid
concentrations predicted to modulate B lymphocytes and disease-associated microglia. Tolebrutinib is being evaluated in phase 3 clinical studies for the treatment of various forms of multiple sclerosis and its safety and efficacy have not been
evaluated by any regulatory authority worldwide. For more information on tolebrutinib clinical studies, please visit
<FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7a00e6"><U>www.clinicaltrials.gov</U></FONT><FONT STYLE="font-family:arial">. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><I>About HERCULES </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">HERCULES (clinical study identifier: NCT04411641) was a double-blind randomized phase 3 clinical study
evaluating the efficacy and safety of tolebrutinib in participants with nrSPMS. nrSPMS was defined at baseline as having a SPMS diagnosis with an expanded disability status scale (EDSS) between 3.0 and 6.5, no clinical relapses for the previous 24
months and documented evidence of disability accumulation in the previous 12 months. Participants were randomized (2:1) to receive either an oral daily dose of tolebrutinib or matching placebo for up to approximately 48 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">The primary endpoint was <FONT STYLE="white-space:nowrap">6-month</FONT> CDP defined as the increase of
<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>1.0 point from the baseline EDSS score when the baseline score is <FONT STYLE="font-family:Times New Roman">&#8804;</FONT>5.0, or the increase of
<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>0.5 point when the baseline EDSS score was &gt;5.0. Secondary endpoints included time to onset of <FONT STYLE="white-space:nowrap">3-month</FONT> CDP as assessed by EDSS score, total number of
new or enlarging T2 hyperintense lesions as detected by MRI, time to onset of confirmed disability improvement, <FONT STYLE="white-space:nowrap">3-month</FONT> change in 9 hole peg test and <FONT STYLE="white-space:nowrap">T25-FW</FONT> test as well
as the safety and tolerability of tolebrutinib. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across
the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while
putting sustainability and social responsibility at the center of our ambitions. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Sandrine
Guendoul</B> | + 33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Evan Berland</B> | + 1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Victor Rouault</B> | +
3333 6 70 93 71 40 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Timothy Gilbert</B> | + 1 516 521 2929 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Thomas Kudsk Larsen</B> | + 44 7545 513 693 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Aliz&eacute; Kaisserian</B> | + 33 6 47 04 12 11 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Felix Lauscher</B>
| + 1 908 612 7239 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Keita Browne</B> | + 1 781 249 1766 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Nathalie Pham</B> | +
33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Tarik Elgoutni</B> | + 1 617 710 3587 | <FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>Thibaud Ch&acirc;telet</B> | + 33 6 80 80 89 90 |
<FONT STYLE="font-family:arial; font-size:9pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi forward-looking statements</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B></B>This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g919252g04g04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">
events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#147;expects&#148;,
&#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes that the expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results
and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any
such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially
successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with
intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,&nbsp;trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the
global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary
Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2023. Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information or statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial">All trademarks mentioned in this press release are the property of the Sanofi
group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g919252g04g04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/3</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d919252dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g919252g01m04.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Duvakitug positive phase 2b results demonstrate <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> potential in ulcerative colitis and Crohn&#146;s disease </I></FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Primary endpoints met in ulcerative colitis (UC) and Crohn&#146;s disease (CD), the most common forms of inflammatory
bowel disease (IBD) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Sanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussions </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Program underscores Sanofi&#146;s Immunology leadership ambition </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><B>Paris and Parsippany, NJ, December</B><B></B><B>&nbsp;17, 2024</B>. Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries
Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn&#146;s disease (CD). RELIEVE UCCD assessed duvakitug, a human IgG1-


<IMG SRC="g919252g44p87.jpg" ALT="LOGO">
2 monoclonal antibody targeting TL1A, for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> inflammatory bowel disease (IBD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">In the RELIEVE UCCD study, 36.2% (low dose) and 47.8% (high dose) of patients with UC treated with duvakitug achieved clinical remission* compared to
20.45% on placebo, placebo-adjusted rates were 15.7% (low dose) and 27.4% (high dose), at week 14 (p=0.050 and 0.003, respectively).* In patients with CD, 26.1% (low dose) and 47.8% (high dose) treated with duvakitug achieved endoscopic response*
compared to 13.0% on placebo, placebo-adjusted rates were 13.0% (low dose) and 34.8% (high dose), at week 14 (p= 0.058 and &lt;0.001, respectively).* Overall, the treatment effect was consistent across subgroups. This is the first and only
randomized, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody in CD. Detailed results are expected to be presented at a scientific forum in 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Duvakitug was generally well tolerated in both UC and CD with no safety signal identified. Overall rates of treatment emergent adverse events (AE) were
similar between duvakitug and placebo across both UC and CD (50% vs 50%). All AEs reported across both UC and CD were less than 5%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><B><I>Houman Ashrafian, MD, PhD </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Executive Vice President, Head of Research&nbsp;&amp; Development at Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;These unprecedented results show that duvakitug could represent the next frontier in treating
ulcerative colitis and Crohn&#146;s disease. If the magnitude of effect persists in the phase 3 program, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options,&#148; said Houman Ashrafian, MD, PhD,
Head of R&amp;D at Sanofi. &#147;The duvakitug program and this partnership underscore Sanofi&#146;s strategy of following the science to identify and rapidly advance breakthrough medicines for patients.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Eric Hughes, MD, PhD </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Head of Global Research&nbsp;&amp; Development and Chief Medical Officer at Teva </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;The results from the RELIEVE UCCD study have exceeded our expectations, and I am deeply moved by the
potential of duvakitug to help treat and meaningfully improve the quality of life of people living with IBD,&#148; said Eric Hughes, MD, PhD, Head of Global R&amp;D and Chief Medical Officer at Teva. &#147;These positive results reinforce
Teva&#146;s ability to develop and accelerate access to innovative medicines. We are excited to collaborate on the next phase of development with our partner, Sanofi, and we would like to thank the investigators and patients who participated in this
study.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Duvakitug is currently under clinical investigation, and its efficacy and safety have not been evaluated by any regulatory
authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g919252g04g04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About IBD </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">UC and CD, the two main types of IBD, are chronic inflammatory conditions of the gastrointestinal (GI) tract resulting in debilitating and persistent
symptoms such as abdominal pain, diarrhea, rectal bleeding, fatigue, and weight loss. Prolonged inflammation can lead to damage within the GI tract, including fibrosis, a common complication of IBD characterized by an excessive accumulation of scar
tissue in the intestinal wall, which may cause narrowing and obstruction often requiring hospitalization and surgery. There is currently no cure for IBD &#150; the goal of treatment is to induce and maintain remission and prevent flares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About the RELIEVE UCCD phase 2b study </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7a00e6"><U>RELIEVE UCCD</U></FONT><FONT STYLE="font-family:arial"> is a <FONT
STYLE="white-space:nowrap">14-week</FONT> phase 2b, randomized, double-blinded, dose-ranging study to determine the efficacy, safety, pharmacokinetics, and tolerability of duvakitug in adults with moderate to severe UC or CD. In the study, patients
who met <FONT STYLE="white-space:nowrap">pre-specified</FONT> inclusion criteria were randomized to receive one of two duvakitug doses or placebo, administered every two weeks subcutaneously, in a 1:1:1 ratio for each indication (UC or CD)
stratified by previous exposure to advanced IBD therapies for 14 weeks. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Participants who completed the
<FONT STYLE="white-space:nowrap">14-week</FONT> induction study were eligible to participate in a long-term extension (LTE) study, currently ongoing. Responders from the induction study could enter the LTE directly into a <FONT
STYLE="white-space:nowrap">44-week</FONT> maintenance period to receive a low or high dose every four weeks. <FONT STYLE="white-space:nowrap">Non-responders</FONT> could enter a <FONT STYLE="white-space:nowrap">14-week</FONT> <FONT
STYLE="white-space:nowrap">re-induction</FONT> period. Responders to <FONT STYLE="white-space:nowrap">re-induction</FONT> entered the <FONT STYLE="white-space:nowrap">44-week</FONT> maintenance period. Participants who responded during the
maintenance period are eligible for an open-label period within the LTE. Primary efficacy endpoints for both the <FONT STYLE="white-space:nowrap">14-week</FONT> induction study and the <FONT STYLE="white-space:nowrap">44-week</FONT> maintenance
study are the number of participants who show clinical remission (as defined by the modified Mayo score) in the UC cohort or the number of participants who show endoscopic response (as defined by the <FONT STYLE="white-space:nowrap">SES-CD</FONT>
endoscopic score for CD) in the CD cohort. The study includes sites in the US, Europe, Israel, and Asia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About duvakitug
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Duvakitug is a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> human IgG1-


<IMG SRC="g919252g44p87.jpg" ALT="LOGO">
2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A, also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drive fibrosis associated with IBD through
binding its receptor, DR3; thus, targeting TL1A with duvakitug may mitigate the over-active immune response in these conditions. Duvakitug is currently in a phase 2b clinical study for the treatment of UC and CD, the two most common types of IBD.
The safety and efficacy of duvakitug have not been reviewed by any regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About the Sanofi and Teva collaboration
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Sanofi and Teva are collaborating to <FONT STYLE="white-space:nowrap">co-develop</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialize</FONT> duvakitug for the treatment of UC and CD. Each company will equally share the development costs globally, and the net profits and losses in major markets, with other markets subject to a
royalty arrangement. Sanofi will lead the phase 3 clinical development program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other
parts of Asia and the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Teva </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics
expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicines. For over 120 years, Teva&#146;s commitment to bettering health has never wavered. Today, the company&#146;s
global network of capabilities enables its 37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how
Teva is all in for better health, visit www.tevapharm.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across
the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g919252g04g04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">
potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our
ambitions. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi Media Relations
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25
|&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan
Berland</B> | + 1 215 432 0234 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nicolas Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>L&eacute;o Le Bourhis</B> | + 33 6 75 06 43 81 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor
Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 |&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy Gilbert</B><B></B>&nbsp;|&nbsp;+ 1 516 521 2929 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas Kudsk Larsen</B> | + 44 7545 513 693 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute; Kaisserian</B><B></B>&nbsp;|&nbsp;+ 33 6 47 04 12 11 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix
Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita Browne</B><B></B>&nbsp;|&nbsp;+ 1 781 249 1766 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni </B>|
+ 1 617 710 3587 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud Ch&acirc;telet</B> | + 33 6 80 80 89 90 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Teva Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><FONT COLOR="#7a00e6"><U>TevaCommunicationsNorthAmerica@tevapharm.com<I></I></U> </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Teva Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><FONT
 COLOR="#7a00e6"><U>TevaIR@tevapharm.com</U> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify"><I>This press release
contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s
management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks
and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and
when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product
candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,&nbsp;trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees and on the global economy as a whole.&nbsp;The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended
December&nbsp;31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </I></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><I>All trademarks mentioned in this press release are the property of the Sanofi group. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Teva Cautionary note regarding forward-looking statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify"><I>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on
management&#146;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or
implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148;
&#147;project,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe&#148; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop duvakitug for the treatment of ulcerative colitis (UC) and Crohn&#146;s disease (CD); our ability to successfully
compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline
and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; the effectiveness of our patents and other measures to
protect our intellectual property rights; and other factors discussed in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the third quarter of 2024, and in our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, including in the section captioned &#147;Risk Factors.&#148; Forward-looking statements speak only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify">*As measured by the Modified Mayo Score (MMS) and as measured by the Simple Endoscopic Score for Crohn&#146;s Disease <FONT
STYLE="white-space:nowrap">(SES-CD),</FONT> respectively. <FONT STYLE="white-space:nowrap">P-values</FONT> reported are <FONT STYLE="white-space:nowrap">one-sided</FONT> at a significance level of 0.10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g919252g04g04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/3</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g919252g01m04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g919252g01m04.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  I )(# 1$  A$! Q$!_\0 JP   P$!  (#              H+" D&!P,$
M!0$!  $% 0                4" P8("0<0   & @$# @ %$ @'      (#
M! 4&!P$("0 2"A$3(105%A<Q02)"8C-CLS0U=3:W.'@Y43)4M%4W5]AQ(R0F
M1G8G$0 " @$# @,$!PD          0(#!!$%!A('(3$R01,4"%%A<2)"5!6A
M8C-#4S0U51;_V@ , P$  A$#$0 _ '^.@#H Z .@#H Z .@#H Z .@#H Z .
M@#H Z 0+YC?+:M2L+YFVMO&FVU]ECJY^=(A-MD)LPE3O,LF#,I,0/22IXX>M
M!&015E<B3$X79P)<<.IA8C$Q):;!9R@#\'@WYH^;+;KDDH77K9-]')Z-L!!8
M<DL',HURC4"R@B48KF3R%"[L$IC,0BAZ(9LD2MR<D9IIZ8X2@)>0B$8'H#8.
M^7.SO-1._EL5C7!<.8JII6RC8,FK%\@Z!R43]N8STI2MT?)$J(S*$YLP#D1Z
M(;:>E+(2GDY $S/<8;VQ["?(AV(YUV!VCDO)?C,CEF^;9'*EFU94X+%G<FXP
MIIB_<-8WA"U70L<K(6*3BM(QV\X5V8X7O'",;<=P]Y9N67CJQW1LDO=N:UZ8
M13Z/N:]+4XR;DGJ_'1-M_3*Z?Z<RC_(GZ9?O)OYT_P!.?R7]:/N/ZWW'7(S_
M (O%_P!EB_Y_].\UZ/SGJ_@?7Y?O&K_Z15^8K_OOA_/\/]7S]'U_M,Z\B/)G
MJ;Q?TV1<FTTU5M*=\6GM$ KZ*HB'ZR[,?4I9)RQKA4:-6MY2D#:0H+,6K5:A
M(W(0& ]]0 1I(3,!(,4YG/G"5RED(R*TX_IJ^10LX02W.<WHQ1:0*B,#^P-$
MQL->S!N0FB!]4O#@HQC/V^>@-E:Q^9=QX6T^,48O^I[RUA7O"U&@/EBU,Q6K
M6;*8J-"3E8\/D54MLU2MI(Q>IAI<=/\ ;!]D+& XR+ #;T6E$=G$8CDTB#RW
MR.)R]A:)1%Y"T*2UC4_1U_;T[LR/+8L*SDI4WNC:K*/),#G(1EC"+'P9Z 75
MY#O**XZM![*F%&(RK&V6NR"+5#++HS3:)B!#8C)T1QB=PB\GL:2N[<V%OC6>
M7DM82UI7<2,[ B3O;/ ,H('*J/\ G T&H=/:E6A-OM++D[&/CT?N2&2%T G]
M?A'\E.,1C"0T[ ?M?C@ ^OVWU^@.ZO&WY"7'KR>60DI&EGJRX#>:Z/NLC;JL
MN"%D,#J^H(^CRX2#YM2"-O4LB+N>SH #4&$97$JQ)BC#0DY 69D(&G^2#EET
MTXK(?!95MA,),W+K/6/Z*N8/ XFLF$UF HJ0V'R12WH0'MS.WM[-A[1 .4N"
MY&1[BLL 1"$+TP MG8GFZ:IM3@I3U9I5?LU;BS1@3.<WG=?UV:H+"+T"=\FL
MQ5CY*"8'X>T1^!8^OT!Y]1/FJ:,S9^1LU\ZU[ 44@6'D$9EC OB=PQ]L":/
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MCRR79F6+R'.>SOCSV';++7D$EI0+K+@56V-7T]<_B9/_ "D>'F41A2M"4'T
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MIZ\-CZWN\G99GVE7O;"+"HM<YL$;B^%1SA""W4KN)4/+Y@@]/DWO3I%8L9[
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9H Z .@#H Z .@#H Z .@#H Z .@#H#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g919252g04g04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g919252g04g04.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X01>:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O,#<O,3 M
M,C(Z,#8Z-3,@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z.$,U-C4U0D)"13@R,3%%1CDY1D(X-#1$,3$T
M,3DW.38B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z.$,U-C4U0D%"13@R
M,3%%1CDY1D(X-#1$,3$T,3DW.38B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IC96(T-3@V-2TR.38W+31B,S(M.6)C92UB
M-3(U,C$V9F)C968B('-T4F5F.F1O8W5M96YT240](G5U:60Z-#1B960V-F4M
M9C1E,2TT,SED+6$W.38M-60V.69D,#<Q8CAC(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3YR<C@S,3 P-CPO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(#DY+C)?,C R
M-%\Q,E\Q-U]$=79A:VET=6<@<&]S:71I=F4@<&AA<V4@,F(@<F5S=6QT<R!D
M96UO;G-T<F%T92!B97-T+6EN+6-L87-S('!O=&5N=&DN9&]C>#PO<F1F.FQI
M/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \
M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  2 #P# 1$  A$! Q$!_\0 I0   P # 0              !P@) P8*"P$!
M  (# 0                4& P0'"!    4# 0('# 4- 0       @,$!08!
M!P@) #81$C46%S<X(A,S8S1D%55&9AA(8A0D&0HQ<8$R4E-4Q&7%MH@Y&A$
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'%_/[$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g919252g44p87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g919252g44p87.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  *  <# 1$  A$! Q$!_\0 7P ! 0                  "0H! 0
M               0   % 00+              0%!@<( @ ! S@2(S059396
M-V@).1$!                     /_:  P# 0 "$0,1 #\ H(9*11>D?=-)
MY+I9,XQ;':4=":8@6XUYC2((U9['(G,^7KYQ24G W485!=68Q:5A:2C!.E7<
E,.VU%A:=<%Q; :C@?'Z)?='ZW.UR!GGS&R^V/RZZSX#OJP?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
